Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Pilulka Lekarny AS's 14-Day RSI or its related term are showing as below:
XPRA:PINK's 14-Day RSI is ranked better than 62.34% of 701
companies
in the Healthcare Providers & Services industry
Industry Median: 50.51
vs XPRA:PINK: 43.79
Pilulka Lekarny AS (XPRA:PINK) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Pilulka Lekarny AS 14-Day RSI Related Terms
Pilulka Lekarny AS 14-Day RSI Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pilulka Lekarny AS 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Pilulka Lekarny AS's 14-Day RSI falls into.
Pilulka Lekarny AS (XPRA:PINK) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS (XPRA:PINK) has a 14-Day RSI of 43.79 as of Aug. 27, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Pilulka Lekarny AS and its competitors. According to the industry distribution chart, Pilulka Lekarny AS ranks #264 out of 701 companies in the Healthcare Providers & Services industry, placing it in the top 37.7%.
Is Pilulka Lekarny AS's 14-Day RSI too high?
Pilulka Lekarny AS's current 14-Day RSI is 43.79. The Healthcare Providers & Services industry median 14-Day RSI is 50.51. Pilulka Lekarny AS's value of 43.79 is 13.3% below this industry median. Based on the distribution chart, Pilulka Lekarny AS ranks #264 out of 701 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pilulka Lekarny AS has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's 14-Day RSI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #264 out of 701 companies for 14-Day RSI. This puts Pilulka Lekarny AS in the upper half of its industry. The industry median 14-Day RSI is 50.51. Pilulka Lekarny AS's value of 43.79 is 13.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 50.51, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pilulka Lekarny AS's current 14-Day RSI of 43.79 is 13.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Pilulka Lekarny AS and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 50.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pilulka Lekarny AS's current 14-Day RSI is 43.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč110.38, compared to a current price of Kč110.00 — trading 0.3% below its estimated fair value. The current 14-Day RSI is 43.79 and 13.3% below the Healthcare Providers & Services industry median of 50.51. Pilulka Lekarny AS's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current 14-Day RSI is 43.79 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be undervalued.
The current stock price of Kč110.00 is trading 0.3% below its estimated GF Value™ of Kč110.38.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
14-Day RSI: 43.79
GF Value™: Kč110.38 vs. price of Kč110.00 (0.3% below fair value)
Industry Position: 13.3% below the Healthcare Providers & Services median (#264 of 701)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
50GF Score
Get the complete analysis for XPRA:PINK
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
